Brendan Smith
2021
In 2021, Brendan Smith earned a total compensation of $7.3M as Chief Financial Officer at CRISPR Therapeutics AG.
Compensation breakdown
| Bonus | $75,000 |
|---|---|
| Non-Equity Incentive Plan | $50,000 |
| Option Awards | $5,641,931 |
| Salary | $93,921 |
| Stock Awards | $1,480,500 |
| Other | $3,688 |
| Total | $7,345,040 |
Smith received $5.6M in option awards, accounting for 77% of the total pay in 2021.
Smith also received $75K in bonus, $50K in non-equity incentive plan, $93.9K in salary, $1.5M in stock awards and $3.7K in other compensation.
Rankings
In 2021, Brendan Smith's compensation ranked 1,627th out of 12,412 executives tracked by ExecPay. In other words, Smith earned more than 86.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,627 out of 12,412 | 87th |
Division Manufacturing | 592 out of 5,498 | 89th |
Major group Chemicals And Allied Products | 220 out of 2,374 | 91st |
Industry group Drugs | 184 out of 2,095 | 91st |
Industry Biological Products, Except Diagnostic Substances | 53 out of 452 | 88th |
Source: SEC filing on April 25, 2022.
Smith's colleagues
We found five more compensation records of executives who worked with Brendan Smith at CRISPR Therapeutics AG in 2021.
2021
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
2021
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
2021
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
2021
James Kasinger
CRISPR Therapeutics AG
General Counsel
2021
Michael Tomsicek
CRISPR Therapeutics AG